Trials / Terminated
TerminatedNCT03452527
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Iconic Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ICON-1 | ICON-1 0.6 mg by intravitreal injection |
| BIOLOGICAL | aflibercept | aflibercept 2 mg by intravitreal injection |
Timeline
- Start date
- 2018-03-26
- Primary completion
- 2019-04-25
- Completion
- 2019-04-25
- First posted
- 2018-03-02
- Last updated
- 2021-04-13
- Results posted
- 2021-03-15
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03452527. Inclusion in this directory is not an endorsement.